JP6426696B2 - 呼吸器疾患の治療のための方法および製剤 - Google Patents

呼吸器疾患の治療のための方法および製剤 Download PDF

Info

Publication number
JP6426696B2
JP6426696B2 JP2016502370A JP2016502370A JP6426696B2 JP 6426696 B2 JP6426696 B2 JP 6426696B2 JP 2016502370 A JP2016502370 A JP 2016502370A JP 2016502370 A JP2016502370 A JP 2016502370A JP 6426696 B2 JP6426696 B2 JP 6426696B2
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
composition according
disease
cem
another embodiment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2016502370A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016513688A5 (cg-RX-API-DMAC7.html
JP2016513688A (ja
Inventor
フェルナンデス，プラブハバシ
Original Assignee
センプラ ファーマシューティカルズ，インコーポレイテッド
センプラ ファーマシューティカルズ，インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by センプラ ファーマシューティカルズ，インコーポレイテッド, センプラ ファーマシューティカルズ，インコーポレイテッド filed Critical センプラ ファーマシューティカルズ，インコーポレイテッド
Publication of JP2016513688A publication Critical patent/JP2016513688A/ja
Publication of JP2016513688A5 publication Critical patent/JP2016513688A5/ja
Application granted granted Critical
Publication of JP6426696B2 publication Critical patent/JP6426696B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/424—Oxazoles condensed with heterocyclic ring systems, e.g. clavulanic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Otolaryngology (AREA)
  • Immunology (AREA)
  • Dispersion Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
JP2016502370A 2013-03-14 2014-03-14 呼吸器疾患の治療のための方法および製剤 Active JP6426696B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361781197P 2013-03-14 2013-03-14
US61/781,197 2013-03-14
PCT/US2014/027214 WO2014152326A1 (en) 2013-03-14 2014-03-14 Methods for treating respiratory diseases and formulations therefor

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2018200696A Division JP6810117B2 (ja) 2013-03-14 2018-10-25 呼吸器疾患の治療のための方法および製剤

Publications (3)

Publication Number Publication Date
JP2016513688A JP2016513688A (ja) 2016-05-16
JP2016513688A5 JP2016513688A5 (cg-RX-API-DMAC7.html) 2017-04-13
JP6426696B2 true JP6426696B2 (ja) 2018-11-21

Family

ID=51581187

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2016502370A Active JP6426696B2 (ja) 2013-03-14 2014-03-14 呼吸器疾患の治療のための方法および製剤
JP2018200696A Active JP6810117B2 (ja) 2013-03-14 2018-10-25 呼吸器疾患の治療のための方法および製剤

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2018200696A Active JP6810117B2 (ja) 2013-03-14 2018-10-25 呼吸器疾患の治療のための方法および製剤

Country Status (9)

Country Link
US (1) US9861616B2 (cg-RX-API-DMAC7.html)
EP (1) EP2968801B1 (cg-RX-API-DMAC7.html)
JP (2) JP6426696B2 (cg-RX-API-DMAC7.html)
CN (1) CN105163785A (cg-RX-API-DMAC7.html)
AU (2) AU2014239959A1 (cg-RX-API-DMAC7.html)
CA (1) CA2905975A1 (cg-RX-API-DMAC7.html)
HK (1) HK1217665A1 (cg-RX-API-DMAC7.html)
RU (1) RU2015138796A (cg-RX-API-DMAC7.html)
WO (1) WO2014152326A1 (cg-RX-API-DMAC7.html)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2801100A1 (en) 2003-03-10 2004-09-23 Optimer Pharmaceuticals, Inc. Macrolides and processes for their preparation
CA2703475A1 (en) 2007-10-25 2009-04-30 Cempra Pharmaceuticals, Inc. Process for the preparation of macrolide antibacterial agents
CN102223794B (zh) 2008-10-24 2017-12-22 森普拉制药公司 使用含三唑的大环内酯治疗抗性疾病的方法
US9937194B1 (en) 2009-06-12 2018-04-10 Cempra Pharmaceuticals, Inc. Compounds and methods for treating inflammatory diseases
CN108310000A (zh) 2009-09-10 2018-07-24 森普拉制药公司 治疗疟疾、结核病和mac疾病的方法
CN105198944B (zh) 2010-05-20 2018-06-01 森普拉制药公司 制备大环内酯和酮内酯及其中间体的方法
EP2613630A4 (en) 2010-09-10 2014-01-15 Cempra Pharmaceuticals Inc HYDROGEN BOND FOR THE PREPARATION OF FLUOROCHETOLIDES FOR THE TREATMENT OF DISEASES
NZ700182A (en) 2012-03-27 2017-02-24 Cempra Pharmaceuticals Inc Parenteral formulations for administering macrolide antibiotics
WO2014152326A1 (en) 2013-03-14 2014-09-25 Cempra Pharmaceuticals, Inc. Methods for treating respiratory diseases and formulations therefor
WO2014145210A1 (en) 2013-03-15 2014-09-18 Cempra Pharmaceuticals, Inc. Convergent processes for preparing macrolide antibacterial agents
CN105246334A (zh) 2013-04-04 2016-01-13 哈佛大学的校长及成员们 大环内酯及其制备和使用方法
JP2017531663A (ja) 2014-10-08 2017-10-26 プレジデント アンド フェローズ オブ ハーバード カレッジ １４員ケトライドならびにそれらの調製および使用の方法
PE20180219A1 (es) * 2015-03-06 2018-01-31 Cempra Pharmaceuticals Inc Procesos para preparar fluorocetolidos
CA2980315A1 (en) 2015-03-25 2016-09-29 President And Fellows Of Harvard College Macrolides with modified desosamine sugars and uses thereof
US9659484B1 (en) * 2015-11-02 2017-05-23 Rapidsos, Inc. Method and system for situational awareness for emergency response
CN106083695B (zh) * 2016-06-21 2018-07-24 四川大学 一系列含薁不对称方酸菁小分子及制备方法和应用
EP3409277A1 (en) * 2017-05-30 2018-12-05 Dompé farmaceutici s.p.a. Il-8 inhibitors for use in the treatment and/or prevention of bacterial secondary infections
US11345878B2 (en) * 2018-04-03 2022-05-31 Novaflux Inc. Cleaning composition with superabsorbent polymer
CN111826296B (zh) * 2019-04-17 2022-06-17 深圳微健康基因科技有限公司 人葡萄球菌及其培养方法和应用
CN110157773B (zh) * 2019-06-05 2021-06-18 华中农业大学 鸡毒支原体对泰乐菌素的耐药判定标准试验方法
JP2023538853A (ja) * 2020-08-31 2023-09-12 インスメッド インコーポレイテッド 新たに診断されたマイコバクテリウム・アビウム・コンプレックス肺感染症の処置方法

Family Cites Families (129)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1354753A (en) 1919-02-11 1920-10-05 E M Lannes Portable building
US2180006A (en) 1936-09-09 1939-11-14 Eastman Kodak Co Process for the separation and refining of amines
GB891817A (en) 1959-04-07 1962-03-21 Upjohn Co Improvements in or relating to injectable tetracyclic preparations
US3843787A (en) 1969-01-15 1974-10-22 Pierrel Spa Water soluble derivative of erythromycin
US3668282A (en) 1970-05-08 1972-06-06 Stauffer Chemical Co Stabilized mixture employing n-(beta-0,0-dialkyldithiophosphoryl) aryl sulfonamides
SE458505B (sv) 1979-07-10 1989-04-10 Lepetit Spa Anvaendningen av rifamycin sv och salter daerav foer framstaellning av en beredning foer behandling av reumatoid artrit samt vissa av salterna och deras framstaellning
US4331803A (en) 1980-06-04 1982-05-25 Taisho Pharmaceutical Co., Ltd. Novel erythromycin compounds
US4474768A (en) 1982-07-19 1984-10-02 Pfizer Inc. N-Methyl 11-aza-10-deoxo-10-dihydro-erytromycin A, intermediates therefor
JPS59175414A (ja) 1983-03-23 1984-10-04 Toyo Jozo Co Ltd マクロライド抗生物質の安定な経口用製剤および安定化法
US4742049A (en) 1986-06-04 1988-05-03 Abbott Laboratories Semisynthetic erythromycin antibiotics
KR960000434B1 (ko) 1986-12-17 1996-01-06 다이쇼 세이야꾸 가부시끼가이샤 에리스로마이신 a유도체 및 그의 제조 방법
EP0283055B1 (en) 1987-09-03 1990-08-29 SOUR PLIVA farmaceutska, Kemijska prehrambena i kozmeticka industrija, n.sol.o. 10-dihydro-10-deoxo-11-azaerythronolide-a-compounds, methods and intermediates for the manufacture thereof and their use in pharmaceuticals and in the manufacture thereof
BE1001869A3 (fr) 1988-10-12 1990-04-03 Franz Legros Procede d'encapsulation liposomiale d'antibiotiques aminoglucosidiques, en particulier de la gentamycine.
IL114589A (en) 1990-11-21 1999-12-22 Roussel Uclaf Intermediates for the preparation of erythromycin derivatives
US5985844A (en) 1992-03-26 1999-11-16 Merck & Co., Inc. Homoerythromycin A derivatives modified at the 4"-and 8A-positions
US5527780A (en) 1992-11-05 1996-06-18 Roussel Uclaf Erythromycin derivatives
FR2697524B1 (fr) 1992-11-05 1994-12-23 Roussel Uclaf Nouveaux dérivés de l'érythromycine, leur procédé de préparation et leur application comme médicaments.
JPH07126172A (ja) * 1993-11-05 1995-05-16 Genichiro Soma Ｌｐｓを含む抗ｍｒｓａ剤及び動物用抗ｍｒｓａ剤
FR2718450B1 (fr) 1994-04-08 1997-01-10 Roussel Uclaf Nouveaux dérivés de l'érythromycine, leur procédé de préparation et leur application comme médicaments.
FR2719587B1 (fr) 1994-05-03 1996-07-12 Roussel Uclaf Nouveaux dérivés de l'érythromycine, leur procédé de préparation et leur application comme médicaments.
US5834428A (en) 1995-04-14 1998-11-10 1149336 Ontario Inc. Glucagon-like peptide-2 and its therapeutic use
FR2739620B1 (fr) 1995-10-09 1997-12-19 Roussel Uclaf Nouveaux derives de la 5-0-desosaminyl 6-o-methyl erythronolide a, leur procede de preparation et leur application a la preparation de produits biologiquement actifs
US6274715B1 (en) 1995-11-08 2001-08-14 Abbott Laboratories Tricyclic erythromycin derivatives
FR2742757B1 (fr) 1995-12-22 1998-01-30 Roussel Uclaf Nouveaux derives de l'erythromycine, leur procede de preparation et leur application comme medicaments
FR2745290B1 (fr) 1996-02-28 1998-04-03 Roussel Uclaf Nouveaux derives de l'erythromycine, leur procede de preparation et leur application comme medicaments
US5719272A (en) 1996-04-02 1998-02-17 Abbott Laboratories 2'-protected 3'-dimethylamine, 9-etheroxime erythromycin A derivatives
DK1291351T3 (da) 1996-09-04 2005-10-24 Abbott Lab 6-O-substituerede ketolider med antibakteriel aktivitet
JP2002514197A (ja) 1996-12-13 2002-05-14 イーライ・リリー・アンド・カンパニー Ｐｓａの酵素活性の阻害物質
US6407074B1 (en) 1997-06-11 2002-06-18 Pfizer Inc C-4″-substituted macrolide derivatives
HN1998000086A (es) 1997-06-11 1999-03-08 Pfizer Prod Inc Derivados de 9 - desofo - 9 aza - 9a - homoeritromicina a - c - 4 sustituidos.
HUP0002252A3 (en) 1997-06-11 2002-01-28 Pfizer Prod Inc 9-oxime erythromycin derivatives, process for preparing them and pharmaceutical compositions containing them
HN1998000159A (es) 1997-10-29 1999-02-09 Monsanto Co Derivados de 9- amino - 3 ceto eritromicina
IL135792A0 (en) 1997-12-01 2001-05-20 Abbott Lab 6-o-alkyl derivatives of erythronolide b
ID27825A (id) 1998-03-26 2001-04-26 Fujisawa Pharmaceutical Co Sediaan lepas lambat
FR2777282B1 (fr) 1998-04-08 2001-04-20 Hoechst Marion Roussel Inc Nouveaux derives de la 2-fluoro 3-de((2,6-dideoxy 3-c-methyl 3-0-methyl-alpha-l-ribohexopyranosyl) oxyl) 6-o-methyl 3-oxo erythromycine, leur procede de preparation et leur application a la synthese de principes actifs de medicaments
US6387885B1 (en) 1998-08-26 2002-05-14 Abbott Laboratories 3′,3′-N-bis-desmethyl-3′-N-cycloalkyl erythromycin derivatives as LHRH antagonists
US6020521A (en) 1998-08-26 2000-02-01 Abbott Laboratories Macrolide LHRH antagonists
FR2785612A1 (fr) 1998-11-10 2000-05-12 Hoechst Marion Roussel Inc Nouveaux derives de l'erythromycine, leur procede de preparation et leur application comme medicaments
FR2786188B1 (fr) 1998-11-24 2002-10-31 Hoechst Marion Roussel Inc Nouveaux derives de l'erythromycine, leur procede de preparation et leur applicaion comme medicaments
KR100317907B1 (ko) 1998-11-24 2001-12-24 김 완 주 신규한 중간체, 이를 이용한 마크로라이드계 항생제의제조방법
WO2000034297A1 (en) 1998-12-10 2000-06-15 Pfizer Products Inc. Carbamate and carbazate ketolide antibiotics
AU1675400A (en) 1999-01-27 2000-08-18 Pfizer Products Inc. Ketolide antibiotics
CA2411293A1 (en) 1999-01-28 2000-07-28 Pfizer Products Inc. Novel azalides and methods of making same
FR2789392B1 (fr) 1999-02-04 2001-10-05 Hoechst Marion Roussel Inc Nouveaux derives de l'erythromycine, leur procede de preparation et leur application comme medicaments
AR023264A1 (es) 1999-04-08 2002-09-04 Hokuriku Pharmaceutical Derivados de eritromicina
JP2000351794A (ja) 1999-04-08 2000-12-19 Hokuriku Seiyaku Co Ltd エリスロマイシン誘導体
IL145777A0 (en) 1999-04-16 2002-07-25 Kosan Biosciences Inc Macrolide antiinfective agents
CA2370743A1 (en) 1999-04-16 2000-10-26 Dennis Hlasta Ketolide antibacterials
US6395300B1 (en) 1999-05-27 2002-05-28 Acusphere, Inc. Porous drug matrices and methods of manufacture thereof
US6420535B1 (en) 1999-06-07 2002-07-16 Abbott Laboratories 6-O-carbamate ketolide derivatives
US6437106B1 (en) 1999-06-24 2002-08-20 Abbott Laboratories Process for preparing 6-o-substituted erythromycin derivatives
AU6183700A (en) 1999-08-06 2001-03-05 Taisho Pharmaceutical Co., Ltd. Erythromycin a derivatives
US6096922A (en) 1999-11-01 2000-08-01 Air Products And Chemicals, Inc. Process for the synthesis of dialkyl, diaryl, and arylalkyl aminosulfur trifluorides
KR100336447B1 (ko) 1999-11-24 2002-05-15 민경윤 클라리스로마이신의 개선된 제조방법
JP2001261694A (ja) 2000-03-06 2001-09-26 Pfizer Prod Inc ケトライド抗生物質
DE60122791T2 (de) 2000-03-15 2007-10-04 Hanmi Pharm. Co., Ltd. Verfahren zur Herstellung von Clarythromycin mit nicht pharmazeutischer Qualität
NZ523693A (en) * 2000-07-10 2004-08-27 Chiron Corp Macrolide formulations for inhalation and methods of treatment of endobronchial infections
US20020115621A1 (en) 2000-08-07 2002-08-22 Wei-Gu Su Macrolide antibiotics
GB0031312D0 (en) 2000-12-21 2001-02-07 Glaxo Group Ltd Macrolides
US7138419B2 (en) * 2000-12-27 2006-11-21 Corus Pharma, Inc. Process for manufacturing bulk solutions and a lyophilized pure α-aztreonam lysinate
WO2002094217A1 (en) 2001-05-18 2002-11-28 Chiron Corporation Methods and unit dose formulations for the inhalation administration of aminoglycoside antibiotics
CA2451391A1 (en) 2001-07-03 2003-01-16 Chiron Corporation C12 modified erythromycin macrolides and ketolides having antibacterial activity
US20030176327A1 (en) 2001-10-25 2003-09-18 Cassell Gail Houston Antibiotics for treating biohazardous bacterial agents
TW200303749A (en) 2002-02-22 2003-09-16 Pharmacia Corp Ophthalmic antibiotic drug formulations containing a cyclodextrin compound and cetyl pyridinium chloride
CA2487424C (en) 2002-05-30 2011-01-04 The Scripps Research Institute Copper-catalysed ligation of azides and acetylenes
CN1681520A (zh) * 2002-06-17 2005-10-12 埃匹吉尼斯医药有限公司 脱氢表雄酮的喷雾剂和采用其组合物治疗哮喘或慢性阻塞性肺部疾病的方法
NZ537717A (en) 2002-07-08 2006-04-28 Pliva Istrazivacki Inst D New compounds, compositions and methods for treatment of inflammatory diseases and conditions
AR043050A1 (es) 2002-09-26 2005-07-13 Rib X Pharmaceuticals Inc Compuestos heterociclicos bifuncionales y metodos para preparar y usar los mismos
ITMI20022292A1 (it) 2002-10-29 2004-04-30 Zambon Spa 9a-azalidi ad attivita' antiinfiammatoria.
CA2801100A1 (en) 2003-03-10 2004-09-23 Optimer Pharmaceuticals, Inc. Macrolides and processes for their preparation
US7163924B2 (en) 2003-04-25 2007-01-16 Chiron Corporation Ketolide derivatives
WO2004096822A2 (en) 2003-04-25 2004-11-11 Chiron Corporation Pyridyl substituted ketolide antibiotics
ATE348837T1 (de) 2003-05-13 2007-01-15 Glaxo Group Ltd Neue 14- und 15-gliedrige ringverbindungen
WO2005007143A2 (en) 2003-07-14 2005-01-27 The Board Of Trustees Of The University Of Illinois Use of makrolides and ketolides for the treatment of tuberculosis
US7457520B2 (en) 2003-07-24 2008-11-25 Time Warner Cable, Inc. Technique for providing a virtual digital video recorder service through a communications network
GB0402578D0 (en) 2004-02-05 2004-03-10 Cambridge Theranostics Ltd Methods of treatment of atherosclerosis
US7468428B2 (en) 2004-03-17 2008-12-23 App Pharmaceuticals, Llc Lyophilized azithromycin formulation
US20060116336A1 (en) 2004-03-17 2006-06-01 American Pharmaceutical Partners, Inc. Lyophilized azithromycin formulation
WO2005105821A2 (en) 2004-04-28 2005-11-10 Alembic Limited Process for the preparation of telithromycin
JP2007536371A (ja) 2004-05-06 2007-12-13 グラクソスミスクライン・イストラジヴァッキ・センタル・ザグレブ・ドルズバ・ゼー・オメイェノ・オドゴヴォルノスティオ 微生物感染症の治療に有用なエステル結合マクロライド
JP2008508322A (ja) 2004-07-28 2008-03-21 ランバクシー ラボラトリーズ リミテッド 抗菌剤としてのケトライド誘導体
US20060076536A1 (en) 2004-09-29 2006-04-13 Barshied Scott R Oxygen scavenging pharmaceutical package and methods for making same
GB0424959D0 (en) 2004-11-11 2004-12-15 Glaxo Group Ltd Novel compounds
GB0424958D0 (en) 2004-11-11 2004-12-15 Glaxo Group Ltd Novel compounds
EP1836212B1 (en) 2005-01-14 2011-09-07 Glaxo Group Limited Macrolide compounds containing biotin and photo-affinity group for macrolide target identification
EP1841437B1 (en) 2005-01-14 2009-04-29 GlaxoSmithKline istrazivacki centar Zagreb d.o.o. 9a-carbamoyl and thiocarbamoyl azalides with antimalarial activity
WO2006075256A2 (en) 2005-01-14 2006-07-20 Glaxosmithkline Istrazivacki Centar Zagreb D.O.O. 9a-carbamoyl-ϝ-aminopropyl- and 9a-thiocarbamoyl-ϝ-aminopropyl-azalides with antimalarial activity
EP1868434A4 (en) 2005-03-22 2011-10-26 Azevan Pharmaceuticals Inc BETA-LACTAMYL ALKANIC ACIDS FOR THE TREATMENT OF PREMIERSTRUELLEN FAULTS
US20070015719A1 (en) 2005-07-07 2007-01-18 Elan Pharma International Limited Nanoparticulate clarithromycin formulations
JP5328349B2 (ja) 2005-07-19 2013-10-30 アゼヴァン ファーマスーティカルズ，インコーポレイテッド ベータ−ラクタミルフェニルアラニン、システイン、およびセリン・バソプレッシン拮抗剤
DK1945654T3 (en) 2005-10-31 2015-11-30 Leo Pharma As CREATING A antibiotic, CRYSTALLINE fusidic
GB0522715D0 (en) 2005-11-08 2005-12-14 Helperby Therapeutics Ltd New use
US20070167382A1 (en) 2005-11-15 2007-07-19 Nina Finkelstein Crystalline and amorphous forms of telithromycin
EP1954294A2 (en) 2005-11-23 2008-08-13 Ranbaxy Laboratories Limited Use of macrolide derivatives for treating acne
WO2007060518A2 (en) 2005-11-23 2007-05-31 Ranbaxy Laboratories Limited Ketolide derivatives as antibacterial agents
DOP2006000268A (es) 2005-12-22 2007-07-31 Pfizer Prod Inc Agentes antibacterianos
CN101045063B (zh) 2006-03-28 2011-01-26 广州朗圣药业有限公司 注射用克拉霉素水溶性制剂
EP2077271A4 (en) 2006-05-01 2010-09-15 Taisho Pharmaceutical Co Ltd Macrolide derivative
US20070281894A1 (en) 2006-06-05 2007-12-06 Auspex Pharmaceuticals, Inc. Preparation and utility of substituted erythromycin analogs
CN101129383B (zh) 2006-08-25 2014-04-02 天津和美生物技术有限公司 含氨基糖苷类抗生素的抗生素复方
CA2703475A1 (en) 2007-10-25 2009-04-30 Cempra Pharmaceuticals, Inc. Process for the preparation of macrolide antibacterial agents
US20090209547A1 (en) 2008-02-15 2009-08-20 In Jong Kim C-8 halogenated macrolides
CN102223794B (zh) 2008-10-24 2017-12-22 森普拉制药公司 使用含三唑的大环内酯治疗抗性疾病的方法
CA2759874C (en) * 2009-04-24 2016-11-08 Mpex Pharmaceuticals, Inc. Methods of treating a pulmonary bacterial infection using fluoroquinolones
US9814657B2 (en) 2009-04-27 2017-11-14 Premier Dental Products Company Buffered microencapsulated compositions and methods
CA2767614C (en) 2009-07-13 2019-01-15 Cempra Pharmaceuticals Inc. Fusidic acid dosing regimens for treatment of bacterial infections
CN108310000A (zh) * 2009-09-10 2018-07-24 森普拉制药公司 治疗疟疾、结核病和mac疾病的方法
US20110119604A1 (en) 2009-11-19 2011-05-19 Clevest Solutions Inc. System and method for a configurable and extensible allocation and scheduling tool
DK2544537T3 (en) 2010-03-10 2017-08-28 Cempra Pharmaceuticals Inc PARENTERAL FORMULATIONS OF MACROLIDE ANTIBIOTICS
PL2550286T3 (pl) 2010-03-22 2016-07-29 Cempra Pharmaceuticals Inc Krystaliczne postaci makrolidu i ich zastosowanie
CN105198944B (zh) 2010-05-20 2018-06-01 森普拉制药公司 制备大环内酯和酮内酯及其中间体的方法
US8247394B2 (en) 2010-06-02 2012-08-21 Cempra Pharmaceuticals Inc. Methods of treating urethritis and related infections using fusidic acid
US9260473B2 (en) 2010-07-19 2016-02-16 Virginia Commonwealth University Bivalent multifunctional ligands targeting Aβ oligomers as treatment for Alzheimer's disease
CA2812044A1 (en) 2010-08-30 2012-03-08 Cempra Pharmaceuticals Inc. Methods of treating bacterial infections through pulmonary delivery of fusidic acid
EP2613630A4 (en) 2010-09-10 2014-01-15 Cempra Pharmaceuticals Inc HYDROGEN BOND FOR THE PREPARATION OF FLUOROCHETOLIDES FOR THE TREATMENT OF DISEASES
WO2012042534A2 (en) 2010-09-28 2012-04-05 Glenmark Generics Limited Processes for the preparation of r-sitagliptin and intermediates thereof
WO2012162439A2 (en) 2011-05-23 2012-11-29 Cem-102 Pharmaceuticals, Inc. Compositions comprising fusidic acid and packages therefor
US10471083B2 (en) * 2011-07-12 2019-11-12 Savara Inc. Formulations of aminoglycoside and fosfomycin in combination for treatment of ventilator associated pneumonia (VAP) and ventilator associated tracheal (VAT) bronchitis
EP2748165B1 (en) 2011-08-27 2016-11-02 Wockhardt Limited 1,6-diazabicyclo[3,2,1]octan-7-one derivatives and their use in the treatment of bacterial infections.
CA2846431A1 (en) 2011-08-29 2013-03-07 Infinity Pharmaceuticals Inc. Heterocyclic compounds and uses thereof
US8461188B2 (en) 2011-10-20 2013-06-11 Trius Therapeutics, Inc. Therapeutic combination of daptomycin and protein synthesis inhibitor antibiotic, and methods of use
NZ700182A (en) 2012-03-27 2017-02-24 Cempra Pharmaceuticals Inc Parenteral formulations for administering macrolide antibiotics
WO2014152326A1 (en) 2013-03-14 2014-09-25 Cempra Pharmaceuticals, Inc. Methods for treating respiratory diseases and formulations therefor
WO2014145210A1 (en) 2013-03-15 2014-09-18 Cempra Pharmaceuticals, Inc. Convergent processes for preparing macrolide antibacterial agents
CN105246334A (zh) 2013-04-04 2016-01-13 哈佛大学的校长及成员们 大环内酯及其制备和使用方法
WO2015123256A1 (en) 2014-02-14 2015-08-20 Cempra Pharmaceuticals, Inc. Compositions and methods for treating diabetes and liver diseases
US20170101365A1 (en) 2014-05-27 2017-04-13 Dipharma Francis S.R.L. Azidoalkylamine salts and their use as intermediates
AU2015301154A1 (en) 2014-08-05 2017-02-23 Cempra Pharmaceuticals, Inc. Powder oral suspension formulations of antibacterial agents
PE20180219A1 (es) 2015-03-06 2018-01-31 Cempra Pharmaceuticals Inc Procesos para preparar fluorocetolidos

Also Published As

Publication number Publication date
RU2015138796A (ru) 2017-04-19
JP2019048826A (ja) 2019-03-28
JP6810117B2 (ja) 2021-01-06
EP2968801A4 (en) 2016-09-07
US20160030396A1 (en) 2016-02-04
WO2014152326A1 (en) 2014-09-25
HK1220418A1 (en) 2017-05-05
RU2015138796A3 (cg-RX-API-DMAC7.html) 2018-03-20
US9861616B2 (en) 2018-01-09
EP2968801A1 (en) 2016-01-20
AU2014239959A1 (en) 2015-10-01
CA2905975A1 (en) 2014-09-25
CN105163785A (zh) 2015-12-16
EP2968801B1 (en) 2018-09-26
AU2018232990A1 (en) 2018-10-11
HK1217665A1 (zh) 2017-01-20
JP2016513688A (ja) 2016-05-16

Similar Documents

Publication Publication Date Title
JP6426696B2 (ja) 呼吸器疾患の治療のための方法および製剤
US11883460B2 (en) Antibiotic compositions for treating bacterial infections
US10792289B2 (en) Use of aerosolized levofloxacin for treating cystic fibrosis
US20130164351A1 (en) Methods of treating bacterial infections through pulmonary delivery of fusidic acid
KR20160150110A (ko) 약동학 개선을 위한 에어로졸 플루오로퀴놀론 제형
US20120237564A1 (en) Use of Aerosolized Antibiotics for Treating Chronic Obstructive Pulmonary Disease
US11382884B2 (en) Method for reducing lung infection
US20110054179A1 (en) Mmp-2 and/or mmp-9 inhibitor
JP2016535774A (ja) 多剤耐性結核治療のための噴霧吸入による免疫化学療法
HK1220418B (en) Methods for treating respiratory diseases and formulations therefor
AU2015275224B2 (en) Use of aerosolized levofloxacin for treating cystic fibrosis
HK1168786B (en) Use of aerosolized levofloxacin for treating cystic fibrosis
HK1168786A (en) Use of aerosolized levofloxacin for treating cystic fibrosis

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170307

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20170307

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20171107

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20180202

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180507

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20180925

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20181025

R150 Certificate of patent or registration of utility model

Ref document number: 6426696

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250